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The cy tolytic activity of interferon (IFN) was evaluated for 
its ability to distinguish between paired se ts of nontumori-
genic/ tumorigenic epidermal cells OB-1 /]B-8; DlIDlIa) as 
well as a set consistin g of non promotable, promotable, and 
tumorigenic epidermal cell lines OB-6 clones 30, 21, and 
RT1 01). The viability of the cell types was measured in a 
microassay using histoplates . IFN-')' and IFN-a/ /3, w hen 
employed singly, demonstrated an equivalent and limited 
effect on the viability of all cell lines. Treatment of non-
tumorigenic and non promotable cell lines w ith the com-
bi nation of IFN-')' + IFN-a/ /3 also caused only a limited 
effect on cell viability, whereas trea tment of tumorigenic 
and promotable cell lines with the combination of IFN s 
caused a marked decrease in cell viability. Thus, the cy-
tolytic effect of IFNs employed in combination but not 
singly was discriminatory between tumorigenic and non-
tumorigenic cells as well as between promotable and non-
Recen tl y, com binations of MuIFN-y with MuIFN-al ,B have been shown to discriminate between nontu-'morigeni c and tumorigenic cell s [1] better than the individual interferons (IFN s). Two paired sets of non-tumorigenic/tum origenic cell s of mouse epiderm al 
origin were studied, 0 11011 a and JB-l /JB-8 [1] . JB-8 and 011 a 
cel ls had developed the tumorigenic state after ex posure to chem-
ical promoto rs w hereas JB-1 and 01 cells were not transformed 
by these promotors. The IFN-al ,B and -y combination had a 
marked synergistic and antiproliferative effect on the tumorigenic 
members of each set (6-fold and 18-fold inhibition, res pectively) 
whereas the combination had only a sli ght antiproliferative effect 
on the nontumorigenic cells (1.9-fold and 2.4-fold inhibition, 
respectively). Interferon gamma has also been observed to ac t 
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Abbreviations: 
E ME M: Eagle's minimal essential medium 
FCS: fe tal calf serum 
IFN: interferon(s) 
NK: natural killer 
PBS: phosphate-buffered sa line 
SC: spleen cell (s) 
TP A: 12- 0 - tet radecanoyl-pho rbol-1 2-acetate 
promotable cells . Addition of cytotoxic effector cel ls was 
found to have a relatively moderate effect on the survival 
of targe t cells that were treated with IFN-')' or IFN-al {3 
separately. Addition of cy to toxic effectors to target cells 
trea ted with the IFN s in combin ation had a discriminato ry 
effect. N ontumorigenic and nonpromotable cells were 
moderately affected; the tum origenic and the promotable 
cell s, however, were markedly affected, resulting in their 
complete (or nearly complete) eradica tion. 
The results demonstrate that combination IFN trea t-
ment: (1) has a discriminatory cy tolytic effect on tul11ori-
genic and promotable cells in contrast to their nontUl110-
rigenicand nonpromotablecounterparts; and (2) w hen added 
to cytotoxic effector cells can co mpletely eradica te tumori-
genic and pro motable cells w hile having a signifi cantly 
lesser effect on nontumorigenic and non promotable cells. 
J 111I1eSt Derll'1ato / 89:136-141 , 1987 
synergisti ca ll y with IFN alpha or IF.N beta in a number of other 
acti vities including antiviral ac tivity [2,3], enhancement of natural 
killer (NK) cell ac tivity [4], antitum or ac ti vity bo th in vivo and 
in vitro [5-7], in vitro bone marrow suppress ive activity [8], and 
direct cytolys is of tumor cell s [9]. The present in vestigation was 
ca rried out to determin e if the cytolytic, as well as the an tipro-
Jifera ti ve, effect of combined IFN s discriminated between these 
tumorigenic and non tumorigeni c cell lines. Second, the effect of 
IFN-al,B andlor IFN-y was also compared on nonpromotabJe 
promotable, and tumorigenic clones derived from theJB-6 mouse 
epidermal cell line. Third, the effect of IFN-acti vated cytotoxic 
effector cells was assessed. 
MATERIALS AND METHODS 
Cells All target cells were obtained from Dr. N . Colburn (Lab-
oratory of Viral Carcinogenesis, National Cancer institute, N .I.H., 
Bethesda, Maryland). JB-1 and JB-8 were derived by treating 
primary BALB/c mouse epidermal cells in culture with N-methyl-
N '-nitrosoguanine and subseq uently esta blishin g long-term lines 
[1 0]. T he 01l011a paired set was obtained from Sencar mice 
after exposure of primary epidermal cells to 7,12-dimethyl-
benz[ a ]anthracene [11]. Promotable (C121) and nonpromotable 
(C130) clones were obtained fromJB-6 cell lines [12], w hi ch were 
derived from BALB/c mouse primary ep iderm al cell cultures [1 0]. 
The RT101 tumorigenic cell line was obtained fro m JB-6 cells 
after exposure to 12-0 -tetradecanoyl-phorbol- 12-aceta te (TP A) 
in agar [1 2]. JB-8, 011a, and RT1 01 cells had the ability to produce 
tumors in animals and to form colonies in soft agar plates and 
were therefore defined as tumorigenic [lOJ. 
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Figure 1. Cytolytic action ofIFNs against the nontu lTIorigenic/tumorigenic epidermal cell pair, JB -1 /JB-8. Individual or combined IFNs were incubated 
with JB-l (A) or JB-8 (B) cells for the indicated times and viability determined via try pan blue exclusion. Syngeneic SC were added to JB-1 (C) or 
JB-8 (D) ta rget with or without IFNs and viability determined after the specified incubation times. The cffector: ta rget ratio was 100:1. Dashed lill e: 
with SC; solid lill e: without Sc. 
T he cells were g rown at 37°C in a humidified 4% CO2 envi-
ronment in plas tic tissue culture flasks (Corning, Corning, N ew 
York) using Eagle's minimal essential medium (EM EM ; Grand 
Island Biological, G rand Island , N ew York) supplemented with 
10% fetal calfserum (FC S; Flo w Laborato ries, M cLean, Virginia), 
penicillin (100 units/ml, Pharm a-T ek, Inc., Alachu a, Florida), and 
strep tom ycin (100 p.g/ml , Pfizer, New York , N ew York). 
Effector lym phoid cells were derived by teasing apart spleens 
fro m syngeneic mice in RPMI-1 640 medium containin g 10% 
FCS, 50 J-tM 2-mercaptoethanol , and antibio tics . Spleen cells were 
washed 3 tim es in this m edium befo re use. 
Interferons M ouse IFN-y was induced in spleen cells o f 8- to 
15-week-o ld C 57BLl6 mice using staphylococcal enterotoxin A 
(SEA) (Microbial Biochemistry Branch, Division of Micro biol-
ogy, Food and Drug Admini stra tion, C incinnati , O hio) [1 3]. The 
crude IFN , having a specific activity of 50 units/m g of pro tein, 
was sequentially chrom atographed on contro lled pore glass beads 
and Ult rogel AcA 54 (LKB, Bromma, Sweden) (14] . The fi nal 
produ ct which was el uted wi th 1 M N aCl in phosphate-buffered 
saline (PBS) had a specific activity of 104 units/m g of pro tein . 
Before studies were initiated w ith this IFN , it was di alyzed for 
24 h against 100 vol o f PBS at 4°C. 
Pa rtiall y purified murine IFN-y preparations were employed 
for these experiments since previous studies using highly purified 
natural and recombinant D N A-deri ved murine fFN s [1 5] have 
shown fo r both the anti vira l and the antip rolife rative acti vities of 
IFNs th at po tentiation was unaffec ted by the pu rity of the IFNs 
and that the potentiating factors in the IFN prepa rations were the 
IFNs themselves. 
Mouse IFN-a l,B was induced in L-929 cells w ith N ewcastle 
disease virus (vaccine st.ra in) and purified 400- fo ld using B SA-
affl-Gel 10 affl11it y ch ro matograph y [1 6]. The purified produ ct 
had a specific acti vity of 107 U / mg of pro tein. We are indebted 
to Dr. J. Georgiades (I.M .L., H ouston, Texas) for this purified 
IFN-a/,B. 
Antiviral assays were done using mouse L-929 cells in the plaque 
reduction assay employing vesicular stom atitis virus [1 7]. O ne 
unit of IFN was defined as the concentration that resulted in a 
50% reduction in the number of plaques and was corrected by 
co mparison with a labora tory reference preparation of mouse 
IFN-al,B that had been calibrated on the W. H .O. international 
reference preparation G002-904-S11 (N . I. H .). 
Cytolytic Assay O ne hundred target cells in a volume of 10 
p.l o f EMEM (with 3% FC S and antibio tics) were added to each 
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Figure 2. Cytolytic action ofIFNs aga inst the nontumorigenic! tumorigenic epidermal cell pair, 01 1011 a, Indi vidual o r combined IFN s were incubated 
with 0 1 (A) or 0 11 a (8) cells for the indicated times and viability determined via try pan blue exclusion. Syngeneic SC were added to 01 (C) or 011 a 
(D) targe ts w ith or without IFNs and viability determined after the specified incubation times. The effec to r : target ratio was 100 :1. Dashed lille: with 
SC; solid lill e: without Sc. 
well of a histoplate (Dynatech Laboratories, Alexandria, Virginia) 
and allowed to adhere for 8 h. T en microliters of tes t preparation 
(either EMEM with 5% FC S alone or containing IFN-a/ f3, IFN-
y, or IFN-a/f3 + IFN-y) were added to the wells. Unfractionated 
spleen cells were added to one half of these wells at an effector: 
target ratio of 100:1. These histoplates were incubated at 37°C in 
a humidified 4% CO2 incubator. After 24, 48, or 72 h duplicate 
\Veils for each trea tment were stained with 5 JLI of 0.4% trypan 
blue solution (Harleco, Gibbstown , N ew Jersey) and the mean 
number of viable cells determined via direct visual enumeration 
using a light microscope [1 4]. Each experim ent was repeated at 
leas t tw ice . 
RESULTS 
Interferon Alpha/Beta + IFN Gamma Causes Greater Cy-
tolytic Activity Against Tumorigenic Than Against Non-
tumorigenic Cells In vitro studies were first carried out to 
determine if possible cytolyti c activities of murine IFNs could be 
potentiated and whether any such potentiated cytolysis could dis-
criminate between non tumorigenic and tumorigenic cells . Rep-
resentative experiments in Fig lA ,B illustrate that each IFN alone 
moderately decreased the number of JB-l (non tumo rigenic) and 
JB-8 (tumorigeni c) cells. While the IFNs in combination dem-
onstrated only a minor anticellular effect on JB-l cells (Fig 1A), 
a >90% decrease of the tumorigenic JB-8 cells w as seen after 24 
h (Fig 1 B). Statistical anal ysis indica ted that a difference of two-
fold was significant at the <0.05 level [1 8]. 
Adding un fr actionated spleen cells (SC) to the non tumorigenic 
JB-1 or tumorigenic JB-8 cells at an effector : target ratio of 100: 
1 as in the representative experiments in Fig 1 C,D (res pectively) 
signifi cantly decreased the target cell number relative to those 
cells grown in medium alone. Each of the individual IFNs was 
effective in producing a further reduction in the number of both 
types of target cells with IFN-y, being the most potent (per an-
tiviralunit) . The IFN-al f3 + IFN-y combination (in the presence 
of SC) decreased the JB-l cell number somewhat beyond that 
observed for the individual IFNs, but this was not statistically 
significarit (Fig lC) . When IFN-al f3 + IFN-y + SC was added 
to the tumorigenicJB-8 targets, a marked (statistically signifi cant) 
anticellular effect w as seen resulting in complete eradication of 
the JB-8 targets when the higher concentration of IFN alpha/beta 
was combined with IFN-y (Fig ID) . These findings show that 
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Figure 3. Cytolyt ic action of lFNs aga inst nonpromotablc C I 30), promotable (C l 21), and tumorigenic (RT IOI) cells . Individual or co mbined IFN s 
were incubated with C l 30 (A), C I 21 (B), or RT I01 (C) cells for the indicated times and viability determined via try pan blue exclusion. Syngeneic 
SC were added to C l 30 (D), C I 21 (E), or RTI OJ (1') targe ts with or w ithout IFNs and viability determined aftcr the specified incubation times. T hc 
effector:ta rget ratio was 100: I . Dashed lille: with SC; solid lillc: without Sc. 
the tumori genic cell line was more sensitive to the cyto lytic act ion 
of the combined IFN s than was the nontumorigenic member of 
the pair and that the presence of effector cells co uld furth er ampl ify 
this difference leadin g to complete eradica tion of the tumorigeni c 
targets. 
Res ults with the 01 (nontumorigenic) /0 11 a (tumorigenic) pair 
were similar to th ose observed w ith JB-l /JB-S as seen in the 
representative experim ents in Fig 2. Although individual IFNs 
did not distinguish between those cell lines, and combined IFN s 
onl y had a moderate anticellular effect on 01 cells (Fig 2A), the 
combined IFNs exhibited a more marked direct cytolytic action 
on 011a cells (Fig 2B). Indi vidual IFNs enhanced the ki lling by 
spleen cells of both 01 and 011a targets to a similar degree, and 
IFN-a/ f3 + -y, in the presence of these effecto r cells, red uced the 
number of 01 targets (Fig 2C) no more than expected from the 
combined effects of the individual IFN s. This combination , how-
ever, enhanced the ki llin g by spleen cells of the 011 a targets (Fig 
2 D) to a much grea ter degree. Complete eradication, however, 
was not observed as w ith the JB-S tumorigenic line. These results 
confirm that tumorigenic members of paired sets of cells are more 
sensitive than their non tumorigenic counterpar ts to both the di-
rect and to the cell-mediated actions of combined IFNs. 
When the non promotable cell line, Cl 30, the promotable but 
nontumorigenic line, Cl 21, or the tumorigenic line, RTI 01, was 
incubated with individual IFNs, a moderate and similar anticel-
lular effect was observed in all 3 cases as illustrated in the rep-
resentative experiments in Fig 3A-C. While the effect of IFN-
a/{3 + -y on Cl 30 was equivalent to the sum of the individual 
ac tions of these IFNs (Fig 3A), this combination exhibited a cy-
tolytic effect on both C l 21 (Fig 3B) and RTI 01 (Fig 3C) much 
grea ter than this sum. 
Adding SC with or without individuallFNs resulted in a similar 
deg ree of cytolysi s of all 3 targets as shown in the representative 
experimen~s in Fig 3D-F. In contrast to the moderate effect of 
combined IFNs plus spleen cells on C l 30 targets (Fig 3D), this 
treatment resulted in a much grea ter degree of cytolys is of both 
C l 21 (F ig 3E) and RTI01 (F ig 3F) terminating in complete 
eradication of these targets. These findin gs dem onstrate that the 
sensitivity of promotable, but nontumorigenic, epidermal cells 
to both direct and cell-mediated cytolysis by combined IFNs 
parallels the sensitivity of their tumorigenic counterparts. 
Tab le I summarizes the results of the cytolytic action of IFNs 
with or without effector SC on the inves tigated targets after 72 
h of incubation . It can be seen that the sensiti vity of these targets 
to the direct or cell-mediated actions of IFN-a/ {3 + -y correlates 
directly with the degree of transfo rmation. 
In order to determ.ine if concentrations of IFN-y greater than 
100 U / ml could discriminate between tumo rigenic and nontLI-
Illorigenic or between nonprol11otable and pro n"lotable cells, these 
targets were investigated with 500 U /ml and with 1000 U /ml of 
IFN- y. N either of these higher concentrations of IFN-y was able 
to selectively affect cells in anyone stage of transformation. This 
observation was true of all 3 sets of target cells both with and 
without effector cells. 
In all of these in vitro experiments, cells that became non-
adherent were observed to take up trypa n blue indica ting that 
IFN did not simply cause the cells to detach but actually killed 
the cell s. Th is was confirmed by observing that w hen detached 
cells were placed in fresh medium containing no IFN , growth 
was not seen. 
In the preceding studies, IFN s and SC were coincubated with 
the target cells. Thus , it was not known to what extent target 
cell death was due to the cell-mediated, as opposed to the direct, 
actions of IFNs. Therefore, SC were preincubated in individual 
or combined IFNs for S h, washed 3 X in PBS and then added 
to JB-l or JB-S targets . Ki lling was enhanced relative to that by 
SC preincubated in medium alone, but was no grea ter on either 
target than that expected from the cell-mediated effects of the 
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Table I. Percent Cytolysis of Epidermal Target Cells by Interferon (IFN) (± SE) 
Nontumorigcnic Tumorigenic Nonpromotable Promotable Tumorigenic 
Treatment" JB-l 01 JB-8 Dlla CL 30 CL 21 RT101 
IFN-a/{3 (10' Ulm l) 21 + 8 27 + 11 15 '+ 9 21 + 15 8 + 3 20 + 12 21 + 8 
IFN- y (102 U/ml) 9 + 3 19 + 6 21 + 10 11 + 7 9 + 4 21 + 10 11 + 6 
IFN-a/{3 (10' U / ml) 28 + 8 34 + 13 77 + 26 69 + 19 21 + 9 69 + 25 57 + 27 
+ IFN-y (102 U/ml) 
IFN-a/{3 (10' U/ml) 24 + 18 38 + 18 30 + 13 22 + 17 54 + 18 57 + 32 63 + 27 
+ spleen cells" 
IFN-y (102 U / ml) 33 + 14 19 + 11 35 + 14 54 + 14 36 + 14 43 + 23 51 + 38 
+ spleen cells 
IFN-a/{3 (10' U / ml) 38 + 16 46 + 23 100 + 0 84 + 16 66 + 33 100 + 0 100 + 0 
+ IFN-y (102 U / ml) 
+ spleen cells 
' IFNs :!: spleen cells were incubated with the targets for 72 h. Viability of targets was then determined via trypan blue exclusion . Each mean (:!: SE) is the average of 5 
independent determinations; each determination is based on cell counts in duplicate wells of a histoplatc. 
bEffector:target cell ratio = 100: I. 
individual IFNs (data not shown). This finding indicates that 
optimal cell-mediated synergistic killing by the combined IFNs 
may require the continued presence of the IFNs. 
DISCUSSION 
The results of the present investigation confirm those of Fleisch-
mann et al [1] that tumorigenic epidermal cells are more sensitive 
to the antiproliferative activity of IFN-aIJ3 + -y. than are non-
tumorigenic members of a matched set. They extend these ob-
servations. however. to show that the tumorigenic epidermal cells 
are more sensitive than their nontumorigenic counterparts to the 
direct cytolytic action of combined IFNs. Furthermore. obser-
vations with promotable cells indicate that combined IFNs may 
also act selectively against non tumorigenic epidermal cells that 
are progressing toward tumorigenicity. This much greater cy-
tolytic potential ofIFN-a/ J3 + -y against tumorigenic (and pro-
motable) versus nontumorigenic cells supports the suggestion that 
combination IFN treatment may have greater therapeutic value 
and lower side effects than high doses of individual IFNs. 
Epidermal cells that are sensitive to promotion to tumori-
genicity by the phorbol ester TP A represent an important step 
in preneoplastic progression [11]. Although these cells are not 
phenotypically tumorigenic as determined by their ability to form 
colonies in soft agar or tumors in animals. they appear genotyp-
ically similar to tumorigenic cells in their sensitivity to the cy-
tolytic effects of combined IFNs. This suggests that combined 
IFNs may have the ability to selectively eliminate preneoplastic 
ce\1s before they reach fuB tumorigenic potential. The mechanism 
by which IFNs recognize and selectively lyse promotable and 
tumorigenic ceBs remains. however. without an explanation. 
The addition of SC was seen to reduce the target cell number 
even in the absence of IFN . When each of the individual IFNs 
was added. however. there was a further decrease in target cells. 
This would be expected on the basis of direct anticellular action 
of the IFNs as well as by the activation of SC by IFN . Most 
striking was the observation that tumorigenic and promotable 
targets were completely eradicated only when both combined 
IFNs and SC were present. illustrating the importance of both 
direct and cell-mediated actions of IFN . It is also notable that JB-
8 cells were more sensitive than D11 a cells to both the direct and 
to the cell-mediated cytolysis by combined IFNs. since the former 
cell line is more tumorigenic [11] . The SC preparation contained 
a heterologous population oflymphoid ce\1 types. many of which 
have been previously shown not only to be activated by IFN [19]. 
but to be more efficiently activated by IFN-y than by IFN-a or 
13. (i. e .• NK cells [20] and macro phages [21]) . This also appeared 
to be the case in the present study since 102 U /ml of IFN-y + 
SC resulted in equal or greater target cell killing than did SC plus 
103-10' D/ml of IFN-aI J3 . These results indicate that effector 
cells are necessary for the maximal killing of tumorigenic (and 
promotable) targets by combined IFNs. 
Tumorigenic target cells coincubated with effector spleen cells 
and IFN-aI J3 + IFN-y were completely eradicated. Effector cells 
preincubated in combined IFN s. however. were less effective In 
eliminating tumorigenic targets . Although observed by other in-
vestigators [22]. this requirement for the continued presence of 
IFNs for the optimal activation of effector cells is not completely 
understood. The findings of the present study . therefore. indicate 
a need for further investigations into mechanisms of direct and 
cell-mediated synergistic actions of IFN-aI J3 + IFN-y. 
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